Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated gl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862055/
https://ncbi.nlm.nih.gov/pubmed/32444867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0868-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars